Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of WVE-120102 in early manifest Huntington's disease
2019-002178-30Phase 2Terminated
- Sponsor
- Wave Life Sciences
- Start
- Aug 2019
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WVE-120102 in Huntington disease (HD), sponsored by Wave Life Sciences. Primary endpoint: Safety and tolerability. Started Aug 2019; status: terminated.
02
Drugs
WVE-120102
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2019-002178-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002178-30.